Coronavirus Update: Novartis Joins Antiviral Therapies Search With Novel DARPin Alliance
Plus: Japan Passes Bill For Free Vaccines
Swiss biotech Molecular Partners will receive upfront payment of CHF60m, including equity.
You may also be interested in...
In the latest example of cross-industry collaboration in these turbulent times, Novartis is joining forces with Pfizer and BioNTech to help produce their in-demand mRNA vaccine at a facility in Switzerland.
The Phase III failure of ruxolotinib contrasts with encouraging results and emergency use authorization for Lilly’s JAK inhibitor baricitinib in combination therapy.
Drug fails to save lives in study and follows disappointments from Roche and Regeneron/Sanofi's IL-6 inhibitors.